このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Avadel Pharmaceuticals マネジメント
マネジメント 基準チェック /34
現在、CEO に関する十分な情報がありません。
主要情報
Greg Divis
最高経営責任者
US$985.2k
報酬総額
| CEO給与比率 | 60.9% |
| CEO在任期間 | 5.7yrs |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 4.8yrs |
| 取締役会の平均在任期間 | 6.2yrs |
経営陣の近況
Recent updates
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10
Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?
Feb 05
CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$106m |
| Mar 31 2024 | n/a | n/a | -US$157m |
| Dec 31 2023 | US$985k | US$600k | -US$160m |
| Sep 30 2023 | n/a | n/a | -US$159m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$142m |
| Dec 31 2022 | US$754k | US$561k | -US$137m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$90m |
| Dec 31 2021 | US$3m | US$545k | -US$77m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$56m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$3m | US$520k | US$7m |
| Sep 30 2020 | n/a | n/a | US$16m |
| Jun 30 2020 | n/a | n/a | US$18m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$1m | US$472k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$94m |
| Jun 30 2019 | n/a | n/a | -US$101m |
| Mar 31 2019 | n/a | n/a | -US$96m |
| Dec 31 2018 | US$685k | US$417k | -US$95m |
| Sep 30 2018 | n/a | n/a | -US$40m |
| Jun 30 2018 | n/a | n/a | -US$2m |
| Mar 31 2018 | n/a | n/a | US$30m |
| Dec 31 2017 | US$1m | US$375k | US$68m |
報酬と市場: Gregの 総報酬 ($USD 985.20K ) は、 US市場 ($USD 5.64M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Gregの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Greg Divis (57 yo)
5.7yrs
在職期間
US$985,200
報酬
Mr. Gregory J. Divis Jr., also known as Greg, has been Director of Avadel Pharmaceuticals plc since June 3, 2019 and has been its Chief Executive Officer since January 2019. Mr. Divis served as an Interim...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 5.7yrs | US$985.20k | データなし | |
| Senior VP | 4.8yrs | US$663.14k | 0.084% $ 1.0m | |
| Chief Commercial Officer | 3.6yrs | US$770.95k | 0% $ 0 | |
| General Counsel & Company Secretary | 4yrs | データなし | 0.0091% $ 111.7k | |
| VP of Corporate and Business Development | 9.2yrs | データなし | 0.17% $ 2.0m | |
| Vice President of Sales | 8.1yrs | データなし | データなし | |
| Vice President of People & Culture | 3.3yrs | データなし | データなし | |
| Consultant | 5.4yrs | US$982.54k | データなし | |
| Senior Vice President of Technical Operations | 4.8yrs | データなし | データなし | |
| Senior Vice President of Medical & Clinical Affairs | no data | データなし | データなし |
4.8yrs
平均在職期間
56yo
平均年齢
経験豊富な経営陣: AVDLの経営陣は 経験豊富 であると考えられます ( 4.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$985.20k | データなし | |
| Member of Scientific Advisory Board | 19.7yrs | データなし | データなし | |
| Independent Director | 4.8yrs | US$449.84k | 0.070% $ 850.5k | |
| Independent Director | less than a year | データなし | データなし | |
| Independent Director | 7.3yrs | US$459.84k | 0.086% $ 1.1m | |
| Member of Scientific Advisory Board | 19.7yrs | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.8yrs | US$452.34k | 0.17% $ 2.1m | |
| Chairman of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Non-Executive Chairman of the Board | 6.2yrs | US$482.34k | 0.13% $ 1.6m | |
| Independent Director | 6.2yrs | US$452.34k | 0.054% $ 665.0k |
6.2yrs
平均在職期間
62yo
平均年齢
経験豊富なボード: AVDLの 取締役会 は 経験豊富 であると考えられます ( 5.9年の平均在任期間)。